Wacker Biotech and PhaseBio Sign License Agreement for ESETEC®-Based Production of Antibody Fragment PB2452
Munich and Jena, April 23, 2019 – WACKER subsidiary Wacker Biotech GmbH and US biopharmaceutical company PhaseBio Pharmaceuticals Inc. signed a license agreement for the production of antibody fragment PB2452. Under the agreement, PhaseBio obtains the right to use both WACKER’s ESETEC®-based production strain and WACKER’s ESETEC® technology to manufacture and commercialize the antibody fragment.För mer information se bifogad pressrelease.